NCT04984356View on ClinicalTrials.gov

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

August 8, 2024

Study Completion Date

August 8, 2024

Conditions
T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Interventions
BIOLOGICAL

WU-CART-007

A single IV infusion of WU-CART-007 Cells on Day 1

Trial Locations (12)

19104

Children's Hospital of Philadelphia, Philadelphia

33612

Moffitt Cancer Center, Tampa

37212

Vanderbilt University, Nashville

53792

University of Wisconsin, Madison

63110

Washington University, St Louis

90027

Children's Hospital Los Angeles, Los Angeles

91010

City of Hope, Duarte

Unknown

Peter MacCallum Cancer Centre, Melbourne

Hospital Saint- Louis, Paris

University Hospital Robert Debre, Paris

Erasmus MC, Rotterdam

Prinses Maxima Centrum, Utrecht

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wugen, Inc.

INDUSTRY